A phase II study of weekly paclitaxel (Taxol) in stage IIIB, IV, or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or 70 years (yrs) of age, with (Paraplatin) administered at disease progression

作者： L Garbo , T Marsland , D Garfield , M Khan , L Asmar